ANI Pharmaceuticals (NASDAQ:ANIP) Posts Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings data on Friday. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.33, RTT News reports. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter last year, the firm posted $0.82 EPS. The firm’s revenue for the quarter was up 43.4% on a year-over-year basis. ANI Pharmaceuticals updated its FY 2025 guidance to 6.270-6.620 EPS.

ANI Pharmaceuticals Trading Down 7.3 %

NASDAQ:ANIP opened at $66.28 on Friday. The stock has a fifty day moving average price of $66.86 and a 200 day moving average price of $60.69. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $77.00. The firm has a market cap of $1.44 billion, a PE ratio of -120.51 and a beta of 0.56.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Friday, April 11th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective on the stock. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $80.13.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. This represents a 0.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $197,792 over the last 90 days. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.